Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Posts Slight Increase in Revenues, Widening Losses for Q2

NEW YORK, Aug. 16 (GenomeWeb News) - Transgenomic reported increased revenues and widening losses for the second quarter of 2004 last week.

 

The company booked $9 million in revenues for the quarter, up from $8.5 million during the same quarter last year.

 

R&D costs decreased to $1.7 million, down from $2.4 million during the same period a year ago.

 

Transgenomic's net loss for the quarter amounted to $15.1 million, or $.52 per share, up from $4.7 million, or $.2 per share, during the second quarter a year ago. This loss included a $12 million non-cash impairment charge related to the company's nucleic acids operating segment.

 

As of June 30, Omaha, Neb.-based Transgenomic had $2.1 million in cash, cash equivalents, and short-term investments.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.